CJC-1295 without DAC Specs: Sequence, MW & CAS
Part of the full CJC-1295 without DAC guide - a synthetic growth hormone-releasing hormone reference compound, identity-verified with a COA on every vial.
In brief
The molecular specification of CJC-1295 without DAC (Mod GRF 1-29) is fully enumerated in the entry, and each value carries structure-function meaning. It is a synthetic GHRH/GRF analog of the tetrasubstituted GHRH(1-29) amide type, a growth hormone secretagogue of the GHRH-receptor agonist class. Its sequence is a 29-residue chain terminating in a C-terminal amide; its average molecular weight is approximately 3367.9 g/mol; its molecular formula is C152H252N44O42; and its no-DAC CAS Registry Number is 863288-34-0, with PubChem CID 56841945. This spoke reads those specifications as a connected story, explaining what the sequence, the C-terminal amide, the four substitutions, the mass and formula, and the registry identifiers each tell a researcher about identity, purity verification, and the structure-activity logic of the molecule, without restating the mechanism narrative covered elsewhere.
To the molecule
Molecular specifications
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 (one-letter, C-terminal amide: Y-[D-A]-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2)The detail
A closer look
01
The 29-residue sequence and C-terminal amide
The sequence is Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2, a 29-amino-acid chain corresponding to the GHRH(1-29) segment, the minimal portion of growth hormone-releasing hormone that retains receptor agonist activity. The terminal -NH2 denotes a C-terminal amide rather than a free carboxylate, a modification common in bioactive peptides that can influence receptor recognition and resistance to C-terminal exopeptidases. The presence of D-Ala at position 2 is already visible in the one-letter rendering Y-[D-A]-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2, signaling that this is an engineered analog rather than the native L-amino-acid sequence.
02
The four substitutions as structure-activity design
Relative to native GRF(1-29), four positions are substituted: D-Ala2, Gln8, Ala15 and Leu27. The entry explains these are placed at metabolically labile or oxidation-prone sites, which is the structure-activity rationale: each substitution hardens a position that would otherwise be a degradation or oxidation liability. D-Ala2 is singled out as conferring DPP-IV resistance. This makes the molecule a worked example for the structure-activity-relationships of GHRH(1-29) substitution analogs research area, where altering specific residues trades native sequence for improved metabolic stability while retaining the GHRH-receptor agonist activity of the 1-29 core. The substitutions are functional engineering choices, not arbitrary changes.
03
Mass, formula, and the DAC contrast
The average molecular weight is approximately 3367.9 g/mol (reported as ~3367.95) and the molecular formula is C152H252N44O42, consistent with PubChem CID 56841945. These values are the constants used to verify identity on a certificate of analysis and to convert mass into molarity for assays. The contrast with the DAC version is instructive: the DAC form carries the extra Nε-maleimidopropionyl-Lys30 albumin-binding extension, giving it formula C165H269N47O46 and a heavier MW of about 3647.2, under a different CAS, 446262-90-4. The roughly 279 g/mol difference is the mass of that albumin-binding handle the no-DAC form lacks, so the formula itself encodes the structural distinction between the two variants.
04
Registry identifiers and verification
The no-DAC form carries CAS Registry Number 863288-34-0 and PubChem CID 56841945, distinct from the DAC variant's CAS 446262-90-4. These identifiers anchor the compound across chemical databases and supplier records: the CAS number disambiguates the no-DAC form from the DAC form in registry and supplier listings, while the PubChem CID links to the formula C152H252N44O42 and the full IUPAC peptide name. For laboratory verification, matching the CAS number, formula and average molecular weight on an incoming certificate of analysis against these reference values confirms that received research material is the no-DAC tetrasubstituted GHRH(1-29) amide and not the heavier albumin-binding DAC analog.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. CJC-1295 without DAC is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.